Recently, another study prepared NTLA-2001, an in vivo gene-editing therapeutic agent, made by lipid nanoparticles encapsulating messenger RNA of Cas9 protein and single guide RNA targeting misfolding transthyretin (TTR) responsible of transthyretin amyloidosis. This evidence concerns the gene TTR and prealbumin measurement.